HCA three-lens brief
Evidence-based stock research on HCA. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 24.4pp over 30 days. · RSI at 30 — technically oversold.
- RSI at 30 — technically oversold.
- Underperforming SPY by 24.4pp over 30 days.
- Analyst mean target $513.10 — 20% above current (21 analysts).
HCA closed at $428.65 (-1.03%) as of 2026-05-04. Market cap: $95.09B. P/E (trailing) 14.8. Positives: analyst mean target $513.10 — 20% above current (21 analysts).. Concerns: rSI at 30 — technically oversold.; underperforming SPY by 24.4pp over 30 days.. Last quarter: Revenue $19.11B, net income $1.62B, free cash flow $5.73B.
Why three lenses on HCA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine HCAacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/HCA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath HCA brief"></iframe>